R-115866: Retinoic acid metabolism-blocking agent treatment of psoriasis treatment of acne

Drugs of the Future

Volumn 32, Issue 12, 2007, Pages 1040-1045

  Wang, Y ^a   Serradell, N ^b  

^a IBC   (United States)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [5,6 DIHYDRO 5,5 DIMETHYL 8 (4 METHYLPHENYL) 2 NAPHTHYL]ETHYNYL]BENZOIC ACID; DERMATOLOGICAL AGENT; N [4 [2 ETHYL 1 (1H 1,2,4 TRIAZOL 1 YL)BUTYL]PHENYL] 2 BENZOTHIAZOLAMINE; RAMBAZOLE; RETINOIC ACID METABOLISM BLOCKING AGENT; UNCLASSIFIED DRUG;

ACNE; ACNE VULGARIS; ARTICLE; CHEILITIS; CLINICAL TRIAL; CONTACT DERMATITIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRY SKIN; ECZEMA; EPISTAXIS; ERYTHEMA; GASTROINTESTINAL DISEASE; GENE EXPRESSION; HEART ATRIUM FIBRILLATION; HUMAN; IC 50; NONHUMAN; PRURITUS; PSORIASIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN FRAGILITY; SKIN PAIN; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; XEROSIS;

EID: 41549134830     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.12.1158897     Document Type: Article

References (27)

1. Lacrampe, J.F.A., Sanz, G.C., Venet, M.G., Mabire, D.J.-P. (Janssen Pharmaceutica NV). N-[4-(Heteroarylmethyl)phenyl]-heteroarylamines. EP 907650, JP 2000503670, US 6124330, US 6486187, US 6833375, US 2003176419, WO 9749704.
2. Voorhees, J.J. Future perspectives for clinical investigation with RAMBAs. J Eur Acad Dermatol Venereol [14th Congr Eur Acad Dermatol Venereol (EADV) (Oct 12-16, London) 2005] 2005, 19(Suppl. 2): Abst SAT12.5.
3. Njar, V.C.O., Gediya, L., Purushottamachar, P. et al. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorg Med Chem 2006, 14(13): 4323-40.
4. Chambon, P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996, 10(9): 940-54.
5. Giguère, V. Retinoic acid receptors and cellular retinoid binding proteins: Complex interplay in retinoid signaling. Endocr Rev 1994, 15(1): 61-79.
6. Orfanos, C.E., Zouboulis, C.C., Almond-Roestler, B., Geilen, C.C. Current use and future potential role of retinoids in dermatology. Drugs 1997, 53(3): 358-88.
7. Muindi, J.R., Frankel, S.R., Huselton, C., De Grazia, F., Garland, W.A., Young, C.W., Warrell, R.P. Jr. Clinical pharmacology of oral all-trans-retinoic acid in patients with acute promyelocyte leukemia. Cancer Res 1992, 52(8): 2138-43.
8. Miller, V.A., Rigas, J.R., Muindi, J.R., Tong, W.P., Venkatraman, E., Kris, M.G., Warrell, R.P. Jr. Modulation of all-trans-retinoic acid pharmacokinetics by liarozole. Cancer Chemother Pharmacol 1994, 34(6): 522-6.
9. Dockx, P., Decree, J., Degreef, H. Inhibition of the metabolism of endogenous retinoic acid as treatment for severe psoriasis: An open study with oral liarozole. Br J Dermatol 1995, 133(3): 426-32.
10. Lucker, G.P., Heremans, A.M.C., Boegheim, P.J., Van de Kerkhof, P.C., Steijlen, P.M. Oral treatment of ichthyosis by the cytochrome P450 inhibitor liarozole. Br J Dermatol 1997, 136(1): 71-5.
11. Van Pelt, J.P., De Jong, E.M., De Bakker, E.S., Van de Kerkhof, P.C. Effects of systemic treatment with liarozole on cutaneous inflammation, epidermal proliferation and differentiation in extensive plaque psoriasis. Skin Pharmacol Appl Skin Physiol 1998, 11(2): 70-9.
12. Stoppie, P., Borgers, M., Borghgraef, P. et al. R115866 inhibits all-trans-retinoic acid metabolism and exerts retinoidal effects in rodents. J Pharmacol Exp Ther 2000, 293(1): 304-12.
13. Verfaille, C.J., Steijlen, P.M., Van de Kerkhof, P.C.M., Stoppie, P., Van Wauwe, J.P., van Rossem, K. R115866 (Rambazole): A potential alternative for retinoids in the treatment of psoriasis. J Eur Acad Dermatol Venereol [2nd Int Congr Psoriasis (June 21-24, Paris) 2007] 2007, 21 (Suppl. 1): Abst P 017.
14. Stoppie, P., Van Wauwe, J., Wouters, L., Borgers, M. Rambazole™, a potent inhibitor of all-trans retinoic acid metabolism, applied topically to mouse tail skin exerts retinoid mimetic activity. 65th Annu Meet Soc Invest Dermal (April 28-May 1, Providence) 2004, Abst 420.
15. Gendimenico, G., Stoppie, P., Van Wauwe, J. et al. R115866: A selective retinoic acid metabolism inhibitor acts topically as a retinoidal agent in cutaneous model systems. 62nd Annu Meet Soc Invest Dermatol (May 9-12, Washington, D.C.) 2001, Abst 952.
16. Gu, Z.-M., Wu, D., Feng, H., Barrett, D. Mass balance, metabolism, and excretion of Rambazole, a novel retinoic acid metabolism-blocking agent (RAMBA) in mice rats and dogs. 14th North Am Meet Int Soc Study Xenobiot (ISSX) (Oct 22-26, Rio Grande) 2006, Abst.
17. Verhaeghe, T., Diels, L. Determination of the retinoic acid metabolism blocking agent R115866 in human plasma by gas chromatography-high resolution mass spectrometry. Chromatographia 2000, 52(Suppl. S): S-109-12.
18. Cools, M., Gauwenbergh, G., Vanhoutte, F., Vandeplassche, L. Tolerability, safety and pharmacokinetics of single and multiple oral dosages of R115866 (Rambazole™) in healthy volunteers. 15th Congr Eur Acad Dermatol Venereol (EADV) (Oct 4-8, Rhodes) 2006, Abst PO35.22.
19. Verfaille, C., Thissen, C.A.C.B., Bovenschen, H.J., Mertens, J., Steijlen, P.M., Van de Kerkhof, P.C.M. Oral R15866 in the treatment of moderate to severe plaque-type psoriasis. J Eur Acad Dermatol Venereol 2007, 21(8): 1038-46.
20. Cools, M., Cauwenbergh, G., Vanhoutte, F., Vandeplassche, L. Tolerability, safety, and pharmacokinetics of single and multiple oral dosages of R115866 in healthy volunteers. J Am Acad Dermatol [65th Annu Meet Am Acad Dermatol (AAD) (Feb 2-7, Washington, D.C.) 2007] 2007, 56(2, Suppl. 2): Abst P2782.
21. van de Kerkhof, P., Mertens, J., Steijlen, P. Oral R115866 in patients with moderate to severe plaque-type psoriasis, safety evaluation from a phase IIa trial. 64th Annu Meet Am Acad Dermatol (AAD) (March 3-7, San Francisco) 2006, Abst P2828.
22. Verfaille, C.J., Coel, M., Boersma, IH., Mertens, J., Borgers, M., Rosseuw, D. Oral R115866 in the treatment of moderate to severe facial acne vulgaris: An exploratory study. Br J Dermatol 2007, 157(1): 122-6.
23. Steijlen, P., Thissen, C., Bovenschen, H.J., Mertens, J., van de Kerkhof, P. Oral Rambazole™, in patients with moderate to severe plaque type psoriasis - A pilot trial. J Eur Acad Dermatol Venereol [14th Congr Eur Acad Dermatol Venereol (EADV) (Oct 12-16, London) 2005] 2005, 19(Suppl. 2): Abst P06.84.
24. Bovenschen, H.J., Otero, M.E., Langewouters, A.M.G. et al. Oral retinoic acid metabolism blocking agent Rambazole™ for plaque psoriasis: An immunohistochemical study. Br J Dermatol 2006, 156(2): 263-70.
25. Positive phase II data for dose-finding study of oral Rambazole. DailyDrugNews.com, July 16, 2007.
26. Hachem, J.P., Verfaille, C., Coel, M., Boersma, Mertens, J., Roseeuw, D. Oral Rambazole™ in the treatment of facial acne vulgaris - A phase IIa trial. 15th Congr Eur Acad Dermatol Venereol (EADV) (Oct 4-8, Rhodes) 2006, Abst PO165.
27. Cools, M., Pavez-Lorie, E., Borgers, M. et al. Effect of topical R115866 (Rambazole™) gel on the expression of biomarkers in the skin of healthy volunteers. 67th Annu Meet Soc Invest Dermatol (May 3-6, Philadelphia) 2006, Abst 240.